A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy

Cell Reports

Volumn 19, Issue 9, 2017, Pages 1874-1887

  Takeda, Yohei ^a   Kataoka, Keisuke ^b   Yamagishi, Junya ^c   Ogawa, Seishi ^b   Seya, Tsukasa ^a   Matsumoto, Misako ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

cancer immunotherapy; double stranded RNA; innate immunity; PD L1 blockade; priming adjuvant; Toll like receptor 3; tumor immunity; tumor associated antigen; vaccine immunotherapy

Indexed keywords

ANTIBODY; ARNAX; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON REGULATORY FACTOR 3; OVALBUMIN; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; CANCER ANTIBODY; CANCER VACCINE; CYTOKINE; IRF3 PROTEIN, HUMAN; TICAM1 PROTEIN, HUMAN; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG RESISTANCE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TUMOR REGRESSION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INNATE IMMUNITY; METABOLISM; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; B7-H1 ANTIGEN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; MICE, INBRED C57BL; OVALBUMIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TOLL-LIKE RECEPTOR 3; TUMOR MICROENVIRONMENT;

EID: 85019978733     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.05.015     Document Type: Article

References (56)

1. Anders, S., Huber, W., Differential expression analysis for sequence count data. Genome Biol., 11, 2010, R106.
2. Anders, S., Pyl, P.T., Huber, W., HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31 (2015), 166–169.
3. Azuma, M., Ebihara, T., Oshiumi, H., Matsumoto, M., Seya, T., Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells. OncoImmunology 1 (2012), 581–592.
4. Azuma, M., Takeda, Y., Nakajima, H., Sugiyama, H., Ebihara, T., Oshiumi, H., Matsumoto, M., Seya, T., Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. OncoImmunology, 5, 2016, e1188244.
5. Bachem, A., Güttler, S., Hartung, E., Ebstein, F., Schaefer, M., Tannert, A., Salama, A., Movassaghi, K., Opitz, C., Mages, H.W., et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J. Exp. Med. 207 (2010), 1273–1281.
6. Bachmann, M.F., Kopf, M., Marsland, B.J., Chemokines: more than just road signs. Nat. Rev. Immunol. 6 (2006), 159–164.
7. Coulie, P.G., Van den Eynde, B.J., van der Bruggen, P., Boon, T., Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14 (2014), 135–146.
8. Coussens, L.M., Zitvogel, L., Palucka, A.K., Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 339 (2013), 286–291.
9. Curiel, T.J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K.L., Daniel, B., Zimmermann, M.C., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9 (2003), 562–567.
10. Curtsinger, J.M., Mescher, M.F., Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22 (2010), 333–340.
11. De Henau, O., Rausch, M., Winkler, D., Campesato, L.F., Liu, C., Cymerman, D.H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539 (2016), 443–447.
12. Eisenbarth, S.C., Colegio, O.R., O'Connor, W., Sutterwala, F.S., Flavell, R.A., Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008), 1122–1126.
13. Fuertes, M.B., Kacha, A.K., Kline, J., Woo, S.R., Kranz, D.M., Murphy, K.M., Gajewski, T.F., Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J. Exp. Med. 208 (2011), 2005–2016.
14. Fuertes, M.B., Woo, S.R., Burnett, B., Fu, Y.X., Gajewski, T.F., Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34 (2013), 67–73.
15. Gajewski, T.F., Woo, S.R., Zha, Y., Spaapen, R., Zheng, Y., Corrales, L., Spranger, S., Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25 (2013), 268–276.
16. Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W.H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., Trial watch: experimental Toll-like receptor agonists for cancer therapy. OncoImmunology 1 (2012), 699–716.
17. Gerner, M.Y., Heltemes-Harris, L.M., Fife, B.T., Mescher, M.F., Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J. Immunol. 191 (2013), 1011–1015.
18. Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.-J., Kefford, R., Wolchok, J.D., Hersey, P., Joseph, R.W., Weber, J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369 (2013), 134–144.
19. Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
20. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
21. Jongbloed, S.L., Kassianos, A.J., McDonald, K.J., Clark, G.J., Ju, X., Angel, C.E., Chen, C.J., Dunbar, P.R., Wadley, R.B., Jeet, V., et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207 (2010), 1247–1260.
22. Joyce, J.A., Fearon, D.T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 348 (2015), 74–80.
23. Kaech, S.M., Cui, W., Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12 (2012), 749–761.
24. Kamphorst, A.O., Ahmed, R., Manipulating the PD-1 pathway to improve immunity. Curr. Opin. Immunol. 25 (2013), 381–388.
25. Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534 (2016), 402–406.
26. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441 (2006), 101–105.
27. Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26 (2008), 677–704.
28. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., Salzberg, S.L., TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol., 14, 2013, R36.
29. Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L., Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31 (2013), 51–72.
30. Lampkin, B.C., Levine, A.S., Levy, H., Krivit, W., Hammond, D., Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. Cancer Res. 45 (1985), 5904–5909.
31. Levine, A.S., Sivulich, M., Wiernik, P.H., Levy, H.B., Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res. 39 (1979), 1645–1650.
32. Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 454 (2008), 436–444.
33. Matsumoto, M., Seya, T., TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv. Drug Deliv. Rev. 60 (2008), 805–812.
34. Matsumoto, M., Tatematsu, M., Nishikawa, F., Azuma, M., Ishii, N., Morii-Sakai, A., Shime, H., Seya, T., Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nat. Commun., 6, 2015, 6280.
35. Mbow, M.L., De Gregorio, E., Valiante, N.M., Rappuoli, R., New adjuvants for human vaccines. Curr. Opin. Immunol. 22 (2010), 411–416.
36. Pantel, A., Teixeira, A., Haddad, E., Wood, E.G., Steinman, R.M., Longhi, M.P., Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation. PLoS Biol., 12, 2014, e1001759.
37. Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., Bronte, V., Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22 (2010), 238–244.
38. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
39. + T cells in B16-melanoma and proliferation of mature T cells in TIS21-knockout mice after T cell receptor stimulation. Exp. Cell Res. 327 (2014), 209–221.
40. Sabbatini, P., Tsuji, T., Ferran, L., Ritter, E., Sedrak, C., Tuballes, K., Jungbluth, A.A., Ritter, G., Aghajanian, C., Bell-McGuinn, K., et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 18 (2012), 6497–6508.
41. Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44 (2016), 924–938.
42. Schietinger, A., Greenberg, P.D., Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35 (2014), 51–60.
43. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
44. Seya, T., Matsumoto, M., The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer. Cancer Immunol. Immunother. 58 (2009), 1175–1184.
45. Seya, T., Takeda, Y., Matsumoto, M., Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia. OncoImmunology, 5, 2015, e1043506.
46. Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
47. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
48. Shime, H., Matsumoto, M., Oshiumi, H., Tanaka, S., Nakane, A., Iwakura, Y., Tahara, H., Inoue, N., Seya, T., Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc. Natl. Acad. Sci. USA 109 (2012), 2066–2071.
49. + intratumor myeloid cells through the TICAM-1 signaling pathway. Cell Death Differ. 24 (2017), 385–396.
50. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., Vitale, I., Goubar, A., Baracco, E.E., Remédios, C., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20 (2014), 1301–1309.
51. Steinman, R.M., Banchereau, J., Taking dendritic cells into medicine. Nature 449 (2007), 419–426.
52. Takeda, Y., Azuma, M., Matsumoto, M., Seya, T., Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy. J. Exp. Clin. Cancer Res., 35, 2016, 143.
53. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
54. Youn, J.I., Nagaraj, S., Collazo, M., Gabrilovich, D.I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181 (2008), 5791–5802.
55. Zelenay, S., van der Veen, A.G., Böttcher, J.P., Snelgrove, K.J., Rogers, N., Acton, S.E., Chakravarty, P., Girotti, M.R., Marais, R., Quezada, S.A., et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162 (2015), 1257–1270.
56. Zou, W., Wolchok, J.D., Chen, L., PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med., 8, 2016, 328rv4.